191 related articles for article (PubMed ID: 34231135)
1. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
Ferrario A; Kanavos P
Soc Sci Med; 2015 Jan; 124():39-47. PubMed ID: 25461860
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
Blonda A; Barcina Lacosta T; Toumi M; Simoens S
Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
[No Abstract] [Full Text] [Related]
5. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
6. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
7. Examining the impact of different country processes for appraising rare disease treatments: a case study analysis.
Whittal A; Nicod E; Drummond M; Facey K
Int J Technol Assess Health Care; 2021 May; 37(1):e65. PubMed ID: 34044899
[TBL] [Abstract][Full Text] [Related]
8. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
Stafinski T; Glennie J; Young A; Menon D
Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
[TBL] [Abstract][Full Text] [Related]
9. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy.
Scheijmans FEV; Zomers ML; Fadaei S; Onrust MR; van der Graaf R; Delden JJMV; van der Pol WL; van Thiel GJMW
BMC Health Serv Res; 2022 Nov; 22(1):1320. PubMed ID: 36333803
[TBL] [Abstract][Full Text] [Related]
12. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
13. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
Robinson MF; Mihalopoulos C; Merlin T; Roughead E
Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
[TBL] [Abstract][Full Text] [Related]
14. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
Allen D; Gillen E; Rixson L
JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
[TBL] [Abstract][Full Text] [Related]
15. "Ready for the future?" - Status of national and cross-country horizon scanning systems for medicines in European countries.
Vogler S
Ger Med Sci; 2022; 20():Doc05. PubMed ID: 35465640
[No Abstract] [Full Text] [Related]
16. Critical Care Network in the State of Qatar.
Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
[TBL] [Abstract][Full Text] [Related]
17. Managed Entry Agreements: Policy Analysis From the European Perspective.
Dabbous M; Chachoua L; Caban A; Toumi M
Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
[TBL] [Abstract][Full Text] [Related]
18. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
19. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
[TBL] [Abstract][Full Text] [Related]
20. Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review.
Ng QX; Ong C; Chan KE; Ong TSK; Lim IJX; Tang ASP; Chan HW; Koh GCH
Health Econ Rev; 2024 Jun; 14(1):42. PubMed ID: 38896399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
